Stock Events

Stock Events

Zentalis Pharmaceuticals 

$3.68
29
-$0.08-2.21% 08:12 Today

Statistics

Day High
3.76
Day Low
3.75
52W High
6.95
52W Low
1.212
Volume
20,112
Avg. Volume
-
Mkt Cap
269.49M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.69
-0.58
-0.48
-0.37
Expected EPS
-0.588889
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-137.06MNet Income

Analyst Ratings

9.67Average Price Target
The highest estimate is 11.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ZNTL. It's not an investment recommendation.
Amazon
8
AMZN
Tesla
7
TSLA
NVIDIA
7
NVDA
Microsoft
6
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap136.88B
Bristol Myers Squibb is a leading biopharmaceutical company that competes with Zentalis in the oncology sector, particularly in developing cancer treatments.
Merck
MRK
Mkt Cap376.37B
Merck & Co., Inc. is a global healthcare company that competes directly with Zentalis in the development of innovative cancer therapies.
Pfizer
PFE
Mkt Cap159.99B
Pfizer Inc. is a pharmaceutical corporation that competes with Zentalis in the research and development of drugs for various types of cancer.
Gilead Sciences
GILD
Mkt Cap181.18B
Gilead Sciences, Inc. is a biopharmaceutical company that competes in the oncology space, particularly in the development of treatments for cancer, similar to Zentalis.
AMGEN
AMGN
Mkt Cap237.52B
Amgen Inc. is a biotechnology company that competes with Zentalis in the field of oncology, focusing on developing innovative cancer treatments.
Abbvie
ABBV
Mkt Cap468.22B
AbbVie Inc. is a pharmaceutical company that competes with Zentalis in developing and marketing advanced therapies for various cancers.
Astrazeneca
AZN
Mkt Cap257.42B
AstraZeneca PLC is a multinational pharmaceutical and biopharmaceutical company that competes with Zentalis in the oncology sector, especially in developing new cancer drugs.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG is a healthcare company that competes with Zentalis in the field of oncology, focusing on cancer drug development.
Novartis
NVS
Mkt Cap301.95B
Novartis AG is a global healthcare company that competes with Zentalis in developing innovative medicines for cancer treatment.
Johnson & Johnson
JNJ
Mkt Cap651.25B
Johnson & Johnson is a diversified healthcare company that competes with Zentalis Pharmaceuticals in the oncology market, particularly in developing and commercializing cancer treatments.

About

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
Show more...
CEO
Julia Marie Eastland
Employees
106
Country
United States
ISIN
US98943L1070

Listings

XNAS
US
ZNTL
BOATS
BOATS
ZNTL.BOATS

0 Comments

Share your thoughts

FAQ

What is Zentalis Pharmaceuticals stock price today?▼
The current price of ZNTL is $3.68 USD — it has decreased by -2.21% in the past 24 hours. Watch Zentalis Pharmaceuticals stock price performance more closely on the chart.
What is Zentalis Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Zentalis Pharmaceuticals stocks are traded under the ticker ZNTL.
Is Zentalis Pharmaceuticals stock price growing?▼
ZNTL stock has risen by +2.17% compared to the previous week, the month change is a -13.16% fall, over the last year Zentalis Pharmaceuticals has showed a +106.59% increase.
What is Zentalis Pharmaceuticals market cap?▼
Today Zentalis Pharmaceuticals has the market capitalization of 269.49M
When is the next Zentalis Pharmaceuticals earnings date?▼
Zentalis Pharmaceuticals is going to release the next earnings report on November 11, 2026.
What were Zentalis Pharmaceuticals earnings last quarter?▼
ZNTL earnings for the last quarter are -0.59 USD per share, whereas the estimation was -0.49 USD resulting in a -20.41% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Zentalis Pharmaceuticals revenue for the last year?▼
Zentalis Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Zentalis Pharmaceuticals net income for the last year?▼
ZNTL net income for the last year is -137.06M USD.
How many employees does Zentalis Pharmaceuticals have?▼
As of August 25, 2026, the company has 106 employees.
In which sector is Zentalis Pharmaceuticals located?▼
Zentalis Pharmaceuticals operates in the Health & Wellness sector.
When did Zentalis Pharmaceuticals complete a stock split?▼
Zentalis Pharmaceuticals has not had any recent stock splits.
Where is Zentalis Pharmaceuticals headquartered?▼
Zentalis Pharmaceuticals is headquartered in SAN DIEGO, United States.